BRIEF published on 05/02/2026 at 14:10, 4 months 9 days ago Changes within the board of directors of PROACTIS SA Board Of Directors Appointment Proactis SA Rebecca Archer Phil Dennant
BRIEF published on 05/02/2026 at 14:10, 4 months 9 days ago PROACTIS SA annonce une restructuration de son conseil d'administration et de nouvelles nominations Gouvernance D'Entreprise Changements De Direction Restructuration Du Conseil D'administration Rebecca Archer Phil Dennant
BRIEF published on 05/02/2026 at 01:35, 4 months 9 days ago UraniumX Remains Financially Robust Ahead of Spring Drilling Athabasca Basin Financial Stability Marketing Agreement UraniumX Discovery Corp. Murphy Lake Drilling
BRIEF published on 05/02/2026 at 01:35, 4 months 9 days ago UraniumX demeure financièrement solide avant les forages de printemps Bassin D'Athabasca Stabilité Financière Accord De Commercialisation UraniumX Discovery Corp. Forage Du Lac Murphy
BRIEF published on 05/02/2026 at 00:55, 4 months 9 days ago CoTec Holdings Announces Annual Incentive Grants Stock Options CoTec Holdings Share Units Incentive Grants TSX Ventures
BRIEF published on 05/02/2026 at 00:55, 4 months 9 days ago CoTec Holdings annonce des primes incitatives annuelles Options D'achat D'actions CoTec Holdings Parts Sociales Subventions Incitatives TSX Ventures
BRIEF published on 05/02/2026 at 00:05, 4 months 9 days ago Redwood AI Corp. Expands AI Models for Enhanced Chemical Synthesis AI Models Redwood AI Predictive Insights Chemical Synthesis Reactosphere
BRIEF published on 05/02/2026 at 00:05, 4 months 9 days ago Redwood AI Corp. développe des modèles d'IA pour une synthèse chimique améliorée Modèles D'IA Redwood AI Perspectives Prédictives Synthèse Chimique Reactosphere
BRIEF published on 05/02/2026 at 00:05, 4 months 9 days ago Onco-Innovations Scales Up PNKP Inhibitor Technology with Dalton Pharma Services IND-enabling Studies Scale-up Market Awareness PNKP Inhibitor Dalton Pharma
BRIEF published on 05/02/2026 at 00:05, 4 months 9 days ago Onco-Innovations accélère le développement de sa technologie d'inhibiteurs de PNKP grâce aux services de Dalton Pharma. Dalton Pharma Inhibiteur De PNKP Sensibilisation Au Marché Mise À L'échelle Études Préparatoires IND
Published on 09/11/2026 at 21:25, 1 hour 6 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 5 hours 31 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 5 hours 31 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 7 hours 6 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 22:15, 16 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 21 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 2 hours 47 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 4 hours 16 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 15 hours 31 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 15 hours 31 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 15 hours 31 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 15 hours 31 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 3 hours ago Availability of the 2026 Interim Financial Report
